As the first surge of the COVID-19 pandemic hit in the spring, the headlines began heralding the need for more robust and secure supply chains and warning about critical drug shortages.
At that point, there was only so much that pharmaceutical companies could do, but a recent analysis by the Healthcare Distribution Alliance, the national organization representing primary pharmaceutical distributors, provided a positive perspective on the industry's performance during the pandemic's first 90 days.The report, titled "The First 90 Days: US Biopharmaceutical Finished Goods Supply Chain Response to COVID-19," was prepared by Deloitte and highlighted the shift of drug distributors' operations owing to COVID-19.
Read more on cidrap.umn.edu